The **Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)** stock has had a volatile period with major stake sales and ratings changes. Industry-leading investment advisors like **Natixis Advisors LLC and AustralianSuper Pty Ltd** have reduced their positions, while others such as **Leader Capital Markets, BofA, and Goldman Sachs** have reiterated a buy rating on the stock, citing reasons like **Austedo growth, branded drug growth and investment narrative shift** post FDA Approval of Pediatric AJOVY. Despite a momentary 6.8% drop adding to annual losses and considerable debt burden, the stock has shown resilience with its stock up by around 20% and 13% over different three-month periods. Celebrated wealth managers and billionaire investors like **David Einhorn and Larry Robbins** have recommended the Healthcare stock, citing it as a potential low price investment with high upside. **Bullish views** are also driven by Teva's progress on 'Pivot to Growth', expected $700M cost savings by 2027, and increasing institutional ownership. **CEO comments** hint at company's transformation, but mixed responses from investors are evident. Future guidance suggests possibility of generic drug price hikes due to tariffs. The last highlight is a potential tie-up with IBD Tech Leader Catalyst that might bring major deals.
Teva Pharmaceutical Stocks News Analytics from Wed, 06 Nov 2024 08:00:00 GMT to Sat, 09 Aug 2025 23:39:57 GMT -
Rating 6
- Innovation 5
- Information 7
- Rumor -4
